Today: 29 April 2026
Browse Category

NASDAQ:SLNO 30 December 2025 - 7 April 2026

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics withdrew its European filing for VIOKAT on Tuesday, halting a regulatory review that was expected to conclude in 2026. The move came one day after Neurocrine Biosciences agreed to acquire Soleno for $2.9 billion in cash, or $53 a share. Vykat XR, Soleno’s only marketed product, generated $190.4 million in 2025 U.S. sales. Neurocrine said it has no immediate plans for a European launch.
7 April 2026
···
Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR

Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR

Neurocrine Biosciences will acquire Soleno Therapeutics for $53 a share in cash, valuing Soleno at $2.9 billion. The deal gives Neurocrine Vykat XR, the only FDA-approved treatment for hyperphagia in Prader-Willi syndrome. Soleno shares last traded at $52.25. The transaction is expected to close within 90 days, pending regulatory and shareholder approval.
7 April 2026
···
Soleno Therapeutics stock jumps nearly 9% today — what SLNO traders are watching next

Soleno Therapeutics stock jumps nearly 9% today — what SLNO traders are watching next

Soleno Therapeutics shares jumped 8.9% to $42.00 Monday, outpacing a broad biotech rally. The move follows attention on VYKAT XR’s U.S. launch, with preliminary 2025 revenue reported at up to $191 million and 1,250 patient starts. Investors are awaiting full financial results in late February and monitoring upcoming investor conference appearances. No new company news was released Monday.
2 February 2026
·
Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

Soleno Therapeutics shares fell 5.6% to $42.95 Friday, underperforming the biotech sector after law firms announced “investigations” tied to past short-seller claims about Vykat XR. The company reported $66 million in quarterly revenue from the drug, approved for Prader-Willi syndrome, with 1,043 patient start forms since March. The stock hovered just above its 52-week low. Next update expected late February.
9 January 2026
··

Stock Market Today

  • Smart Share Global Withdraws ADS Listing from Nasdaq
    April 29, 2026, 1:50 PM EDT. Smart Share Global Ltd has formally withdrawn its American Depositary Shares (ADS) listing from the Nasdaq Stock Market. The move was confirmed through the filing of Form 25 with the U.S. Securities and Exchange Commission, which notifies the removal of a security from exchange listing and registration. Nasdaq executed the delisting based on regulatory compliance provisions under the Securities Exchange Act of 1934. Smart Share Global, headquartered in Shanghai, China, did not disclose detailed reasons behind the withdrawal. This development marks a significant shift for the Chinese firm's market presence in the United States, raising questions about future listing strategies or market focus.

Latest article

Sagtec Global Stock Jumps After Record 2025 Revenue, but Costs Tell a Harder Story

Sagtec Global Stock Jumps After Record 2025 Revenue, but Costs Tell a Harder Story

29 April 2026
Sagtec Global reported 2025 audited revenue of $19.1 million, up 49%, driven by strong growth in services. Shares surged 38% to $2.35 in U.S. trading after volatile swings. Operating income dropped 9% to $2.1 million and earnings per share fell to $0.09 from $0.16, reflecting higher costs after the Nasdaq IPO. Net cash from operations rose 187% to $4.1 million.
Dow Jones Today: Why the Blue-Chip Index Is Sliding Before Powell, Big Tech and the Oil Shock

Dow Jones Today: Why the Blue-Chip Index Is Sliding Before Powell, Big Tech and the Oil Shock

29 April 2026
The Dow Jones Industrial Average dropped 320 points, or 0.65%, to 48,821.82 Wednesday afternoon, heading for a fifth straight loss as investors awaited the Federal Reserve’s rate decision and major tech earnings. Brent crude surged 7.14% to $119.20 after reports of a possible extended Iran blockade. Boeing and Goldman Sachs weighed on the Dow, while Amazon rose and Microsoft slipped in midday trading.
Go toTop